Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | LSS | P48449 | 1/20 | 0.32 |
| ▸ | THRA | P10827 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25199783 | 0.91 | APP (0.39) | APPLTA4HPTGS1PDE4ALMNA | |
| SCHEMBL16063018 | 0.89 | APP (0.38) | APPLTA4HPTGS1PDE4ALMNA | |
| SCHEMBL23016833 | 0.89 | APP (0.38) | APPLTA4HPTGS1PDE4ALMNA | |
| SCHEMBL16063023 | 0.88 | APP (0.37) | APPLTA4HPTGS1PDE4ALMNA | |
| SCHEMBL10985301 | 0.86 | LTA4H (0.40) | APPLTA4HMAPTPTGS1PDE4A | |
| SCHEMBL17058738 | 0.85 | APP (0.38) | APPLTA4HPTGS1PDE4ALMNA | |
| SCHEMBL28450976 | 0.84 | APP (0.41) | APPLTA4HPTGS1PDE4ALMNA | |
| SCHEMBL5263631 | 0.83 | S1PR2 (0.41) | APPLTA4H | |
| SCHEMBL17058740 | 0.83 | LTA4H (0.44) | APPLTA4HPTGS1PDE4ALMNA | |
| SCHEMBL5335869 | 0.83 | KDM4C (0.40) | APPLTA4HPTGS1PDE4ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116693801-A | Zwitterionic polyurethane and preparation method and application of zwitterionic polyurethane-based ionic gel | 浙江禾欣新材料有限公司 | 2023-09-05 | — | — | CN | disclosed |
| CN-111406081-A | Radiation curable polyurethane resins for inkjet inks | 爱克发有限公司 | 2020-07-10 | — | — | CN | disclosed |
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2014-11-06 | — | — | US | disclosed |
| US-8835654-B2 | Method and compositions for treating amyloid-related diseases | BHI LIMITED PARTNERSHIP (CA) | 2014-09-16 | — | — | US | disclosed |
| US-20140107027-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BHI LIMITED PARTNERSHIP (CA) | 2014-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | APP 1/4885LTA4H 471/4885MAPT 14/4885 |
| US-20140107027-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | APP 1/4885LTA4H 471/4885MAPT 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.